Glossary | Oncology Pipeline

1L

first line

2L

second line

3L

third line

4EBP1

eukaryotic translation initiation factor 4E binding protein 1

53BP1

p53 binding protein 1

aBC

advanced breast cancer (locally advanced [inoperable] or metastatic breast cancer)

Ac

actinium

ADA

anti-drug antibody

ADC

antibody drug conjugate

ADCC

antibody-dependent cellular cytotoxicity

ADP

adenosine diphosphate

ADT

androgen-deprivation therapy

AE

adverse event

AESI

adverse event of special interest

AI

aromatase inhibitor

AIHA

autoimmune hemolytic anemia

AJCC

American Joint Committee on Cancer

AJCC v7

American Joint Committee on Cancer version 7

AKT

protein kinase B/also known as PKB

ALK

anaplastic lymphoma kinase

ALT

alanine aminotransferase

AML

acute myeloid leukemia

AMP

adenosine monophosphate

ANC

absolute neutrophil count

anti-HBc

anti–hepatitis B core antibody

anti-HBs

anti–hepatitis B surface antibody

AoV

ampulla of Vater

APF12

alive and progression free survival at 12 months

AR

androgen receptor

ARPI

androgen receptor pathway inhibitor

ASCO/CAP

American Society of Clinical Oncology / College of American Pathologists

AST

aspartate aminotransferase

ATM

ataxia telangiectasia mutated

ATP

adenosine triphosphate

ATR

ataxia telangiectasia and Rad3-related

AUC

area under the curve

AV

acalabrutinib plus venetoclax

B-ALL

B-cell acute lymphoblastic leukemia

BC

breast cancer

BCC

basal cell carcinoma

BCG

Bacillus Calmette-Guérin (biologic)

BCL2

B-cell leukemia/lymphoma 2 protein

BCL6

B-cell lymphoma 6

BCLC

Barcelona Clinic Liver Cancer

BCMA

B-cell maturation antigen

BCR

B-cell receptor

BICR

blinded independent central review

BID

twice daily

BLNK

B-cell linker

BM

brain metastases

BM

Bone marrow

BMFI

brain metastases-free interval

BOR

best overall response

BPDCN

blastic plasmacytoid dendritic cell neoplasm

BR

bendamustine/rituximab

BRAF

v-raf murine sarcoma viral oncogene homolog B1

BRCA

breast cancer susceptibility gene

BRCA 1/2

breast cancer susceptibility gene 1/2

BRCAm

BRCA mutated

BSA

body surface area

BTCs

biliary tract cancers

BTK

Bruton tyrosine kinase

BTKi

BTK inhibitor

c-MET

hepatocyte growth factor receptor

C1D1

Cycle 1 Day 1

CAP/CLIA

College of American Pathologists/Clinical Laboratory Improvement Amendments

CAR

chimeric antigen receptor

CAR-T

chimeric antigen receptor T cell (therapy)

CBR

clinical benefit rate

CBR24

clinical benefit rate at 24 weeks

CCNE1/ CycE

cyclin E1

cCRT

concurrent chemoradiation therapy

CD123

cluster of differentiation

CD19

cluster of differentiation 19

CD20

cluster of differentiation 20

CD23

cluster of differentiation 23

CD28

cluster of differentiation 28

CD3

cluster of differentiation 3

CD5

cluster of differentiation 5

CD73

cluster of differentiation 73

CD8

cluster of differentiation 8

CD80

cluster of differentiation 80

CD86

cluster of differentiation 86

CDK

cyclin-dependent kinase

CDK2

cyclin-dependent kinase 2

CDK4/6

cyclin-dependent kinase 4/6

CDK4/6i

cyclin-dependent kinase 4/6 inhibitor

CDKN1A

cyclin-dependent kinase inhibitor 1A

CHEK

checkpoint kinase

CHF

congestive heart failure

CHK2

serine/threonine-protein kinase Chk2

cHL

classical Hodgkin’s lymphoma

CIRS

Cumulative Illness Rating Scale

CIRS-G

Cumulative Illness Rating Score-Geriatric

CIS

carcinoma in situ

CLDN18.1

Claudin 18.1 isoform

CLDN18.2

Claudin 18 isoform 2

CLL

chronic lymphocytic leukemia

cMET

Tyrosine-protein kinase MET

CNS

central nervous system

CPR

complete pathological response

CPS

combined positive score

CR

complete response

CRC

colorectal cancer

CrCL

creatinine clearance

CRPC

castration-resistant prostate cancer

CRR

complete response rate

CRS

cytokine release syndrome

CRT

chemoradiotherapy

cStage

clinical stage

CT

chemotherapy

cTACE

conventional transarterial chemoembolization

CTCAE

Common Terminology Criteria for Adverse Events

CTCAE v.5

Common Terminology Criteria for Adverse Events version 5

ctDNA

circulating tumor DNA

CTLA-4

cytotoxic T–lymphocyte-associated antigen-4

CYP3A4

Cytochrome P450 3A4

D

durvalumab

DAR

drug-to-antibody ratio

Dato-DXd

datopotamab deruxtecan

DCIS

ductal carcinoma in situ

DCO

data cut-off

DCR

disease control rate

dCRT

definitive chemoradiation therapy

DDFS

distant disease-free survival

DEB-TACE

drug-eluting bead-TACE

DFI

disease-free interval

DFS

disease-free survival

DLBCL

diffuse large B-cell lymphoma

DNA

deoxyribonucleic acid

DNA-PK

DNA-dependent protein kinase

dnTGFβRII

dominant negative TGFβ receptor 2

DoR

duration of response

DoT

duration of treatment

DRFI

distant recurrence-free interval

DRFS

distant relapse-free survival

DSB

double-strand break

DXd

deruxtecan

E2F

transcription factor E2F

eBC

early breast cancer

EBV

Epstein-Barr virus

eCCA

extrahepatic cholangiocarcinoma

ECG

electrocardiogram

ECHO

echocardiogram

ECOG

Eastern Cooperative Oncology Group

ECOG PS

Eastern Cooperative Oncology Group Performance Score

EFS

event-free survival

EGFR

epidermal growth factor receptor

EGFRm

epidermal growth factor receptor mutation

EGFRwt

epidermal growth factor receptor wild type

EMT

epithelial-mesenchymal transition

EORTC

European Organization for Research and Treatment of Cancer

EORTC QLQ-C30

European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire

EORTC QLQ-NMIBC24

European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Non-Muscle-Invasive Bladder Cancer 24

EORTC-IL

European Organization for Research and Treatment of Cancer-Item Library

EP

carboplatin or cisplatin + etoposide

EQ-5D-5L

EuroQol-5 Dimensions-5 Levels

ER

estrogen receptor

ER+

estrogen receptor positive

ERE

estrogen response element

ERK

extracellular signal-regulated kinase

ERα

estrogen receptor alpha

ES-SCLC

extensive stage small-cell lung cancer

ESCC

esophageal squamous cell carcinoma

ESMO

European Society for Medical Oncology

ESR1

estrogen receptor 1

ESR1m

estrogen receptor 1 mutation

ET

endocrine therapy

EV

enfortumab vedotin

Ex19del

exon 19 deletion

FACT-BL

functional assessment of cancer therapy-bladder

FAK

focal adhesion kinase

Fc

fragment crystallizable region

FCR

fludarabine/cyclophosphamide/rituximab

FDA

Food & Drug Administration

FDG

fluorodeoxyglucose

FFPE

formalin-fixed paraffin-embedded

FH

fumarate hydratase

FIGO

International Federation of Gynecology and Obstetrics

FISH

fluorescence in situ hybridization

FKSI

Functional Assessment of Cancer Therapy-Kidney Symptom Index

FL

Follicular lymphoma

FLOT

fluorouracil, leucovorin, oxaliplatin and docetaxel

FLT3-ITD

FMS-like tyrosine kinase internal tandem duplication

FOLFOX

folinic acid (leucovorin), fluorouracil (5-FU), oxaliplatin

FOLH1

folate hydrolase 1

FOXO

forkhead box protein O subclass

FRα

folate receptor α

G1 phase

gap/growth phase I

G1/S

gap/growth phase I/DNA synthesis phase

G2 phase

gap/growth phase II

GAB1

GRB2-associated binding protein 1 of 40 kDa

GBC

gallbladder cancer

GDP

guanosine diphosphate

GEJ

gastroesophageal junction

GELF

Groupe d'Étude des Lymphomes Folliculaires

Gem-Cis

gemcitabine and cisplatin

GHS

global health status

GI

gastrointestinal

gp130

glycoprotein 130

GPC3

glypican-3

GPCR

G-protein coupled receptor

GPRC5D

G protein-coupled receptor, class C, group 5, member D

GRB2

growth factor receptor-bound protein 2

GTP

guanosine triphosphate

GTPase

guanosine triphosphatase

Gy

gray

H2AX

H2A histone family member X

HBcAb

hepatitis B core antibody

HBsAg

HBV surface antigen

HBV

hepatitis B virus

HCC

hepatocellular carcinoma

HCV

hepatitis C virus

HDV

hepatitis D virus

HER2

human epidermal growth factor receptor 2

HER2-

human epidermal growth factor receptor 2 negative

HGBL

High Grade B-cell Lymphoma

HGF

hepatocyte growth factor

HIV

human immunodeficiency virus

HLA

human leukocyte antigen

HLA-E

HLA class I histocompatibility antigen E

HNSCC

head and neck squamous cell carcinoma

HR

hormone receptor

HRQoL

health-related quality of life

HRRm

homologous recombination repair gene mutation

HRT

hormone replacement therapy

HSPC

hormone-sensitive prostate cancer

I

induction

I&T

Imaging & Therapy

IASLC

International Association For The Study Of Lung Cancer

IBCFS

invasive breast cancer-free survival

ICANS

immune effector cell-associated neurotoxicity syndrome

ICC

investigator’s choice of chemotherapy

iCCA

intrahepatic cholangiocarcinoma

ICF

informed consent form

ICR

independent central review

ICT

investigator's choice therapy

iDFS (IDFS)

invasive disease-free survival

IgG

immunoglobulin G

IgG1

immunoglobulin G1

IHC

immunohistochemistry

IKK

I kappa B kinase

IL-3Rα

interleukin 3 receptor alpha

ILD

interstitial lung disease

imAEs

immune-mediated adverse events

IMP

investigational medicinal product

IO

immuno-oncology

IP

investigational product

IPI

International Prognostic Index

IRC

independent review committee

IRRs

infusion-related reactions

ISH

in-situ hybridization

ITAM

immunoreceptor tyrosine-based activation motif

ITP

idiopathic thrombocytopenic purpura

ITT

intention-to-treat

IV

intravenous

IVES

intravesical

iwCLL

International Workshop on Chronic Lymphocytic Leukemia

KAP1

Krüppel-associated box domain-associated protein 1

KEAP1

Kelch-like ECH-associated protein 1

KRAS

Kirsten rat sarcoma viral oncogene homolog

L858R

exon 21 L858R point mutation

LBCL

large B cell lymphoma

LCK

lymphocyte-specific protein tyrosine kinase

LDT

lymphocyte doubling time

LHRH

luteinizing hormone-releasing hormone

LIF

leukemia inhibitory factor

LIG III

DNA ligase 3

LKB1

liver kinase B1

LRT

locoregional treatment

LS-SCLC

limited-stage small cell lung cancer

LVEF

left ventricular ejection fraction

LVI

lymphovascular invasion

LYN

Lck/Yes-related novel protein tyrosine kinase

M

maintenance

M phase

mitotic phase

M1

distant metastasis-cancer has spread to other parts of the body

mAb

monoclonal antibody

MAPK

mitogen-activated protein kinase

mBC

metastatic breast cancer

MCL

mantle cell lymphoma

mCRPC

metastatic castration-resistant prostate cancer

MDC1

mediator of DNA damage checkpoint protein 1

MDS

myelodysplastic syndrome

MEK

mitogen-activated protein kinase

MET

MET proto-oncogene, receptor tyrosine kinase

MHC

major histocompatibility complex

mHSPC

metastatic hormone-sensitive prostate cancer

MIBC

muscle invasive bladder cancer

MM

multiple myeloma

MMAE

monomethyl auristatin E

mNSCLC

metastatic NSCLC

mo

months

MOA

mechanism of action

MPR

major pathologic response

MRD

minimal residual disease

MRD+

minimal residual disease positive

mRECIST

modified Response Evaluation Criteria in Solid Tumors

MRI

magnetic resonance imaging

MRN

MRE11-RAD50-NBS1

MSS-CRC

microsatellite stable-colorectal cancer

MTA

methylthioadenosine

MTAP

5′-methylthioadenosine phosphorylase

mTOR

mechanistic or mammalian target of rapamycin

mTORC

mammalian target of rapamycin complex

mTPI-2

modified toxicity probability interval

MTR-1P

methylthioribose-1-phosphate

MUGA

multigated acquisition

MYC

myelocytomatosis viral oncogene

NAD

nicotinamide adenine dinucleotide

NCI

National Cancer Institute

NEC

large cell neuroendocrine carcinoma

NF-κB

nuclear factor kappa-light-chain-enhancer of activated B cells

NFAT

nuclear factor of activated T cells

NHL

non-Hodgkin's lymphoma

NK

natural killer

NKG2A

natural killer cell lectin-like receptor

NMIBC

non-muscle-invasive bladder cancer

non-GCB DLBCL

non-germinal center B-cell diffuse large B-cell lymphoma

NPM1

nucleophosmin gene 1

NSCLC

non-small cell lung cancer

NTRK

neurotrophic tyrosine receptor kinase

OC

ovarian cancer

OD

once daily

OFS

ovarian function suppression

ORR

overall or objective response rate

OS

overall survival

OS-12

overall survival at 12 months

OS-24

overall survival at 24 months

OTRR

objective tumor response rate

p110

catalytic subunit of PI3K

P2X7

P2X purinoceptor 7

P2Y2

P2Y purinoceptor 2

p85

regulatory subunit of PI3K

PAK

p21 activated kinase

PALB

partner & localizer of BRCA gene

PARP

poly (ADP-ribose) polymerase

PARP1

poly (ADP-ribose) polymerase 1

PB

Peripheral blood

pcARPI

physician’s choice of androgen receptor pathway inhibitor

PCI

prophylactic cranial irradiation

pCR

pathological complete response

PCR

polymerase chain reaction

PCWG-3

Prostate Cancer Clinical Trials Working Group 3

PD

progressive disease

PD-1

programmed cell death-1

PD-L1

programmed cell death-ligand 1

PD-L2

programmed cell death-ligand 2

PDAC

pancreatic ductal adenocarcinoma

PDC

platinum doublet chemotherapy

pDC

plasmacytoid dendritic cell

PDK

phosphoinositide-dependent kinase

pDS

pathologic downstaging

PFS

progression-free survival

PFS-12

progression-free survival at 12 months

PFS-18

progression-free survival at 18 months

PFS2

time to second progression or death

PFS24

PFS at 24 months from randomization

ph3

Phase 3

PI

prescribing information

PI3K

phosphoinositide 3-kinase

PIK3CA

phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha

PIP2

phosphatidylinositol 4,5-bisphosphate

PIP3

phosphatidylinositol (3,4,5)-trisphosphate

PK

pharmacokinetics

PKC

protein kinase C

PLC

phospholipase C

PLL

prolymphocytic leukemia

pLOT

prior line of therapy

PML

progressive multifocal leukoencephalopathy

PNK1

polynucleotide kinase/phosphatase 1

PO

per oral

POLB

DNA polymerase beta

PORT

post-operative radiation therapy

PPI

proton-pump inhibitor

PR

partial response

PRAEs

possibly related to treatment adverse events

pRCC

papillary renal cell carcinoma

PRMT5

protein arginine methyltransferase 5

PRO

patient-reported outcomes

PRO-CTCAE

Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events

PS

phosphatidylserine

PSA

prostate-specific antigen

PSMA

prostate-specific membrane antigen

PtCh

platinum-based chemotherapy

PTEN

phosphatase and tensin homolog

PVT

portal vein thrombosis

PVTT

portal vein tumor thrombosis

Q*W

every * weeks

Q28

every 28

Q3W

every 3 weeks

Q4W

every 4 weeks

Q6W

every 6 weeks

Q9W

every 9 weeks

QD

once daily

QLC-CLL-17

Quality of Life Questionnaire - Chronic Lymphocytic Leukemia Module-17

QLQ-BIL21

21-item Cholangiocarcinoma and Gallbladder Cancer Quality of Life Questionnaire

QLQ-C30

Quality of life Questionnaire-C30

QnW

every n weeks

QoL

quality of life

QTcF

QT interval corrected by Fridericia’s formula

QW

every week

R

randomization

R-CHOP

rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone

R/R

relapsed/refractory

R0

no residual tumor

R1

microscopic residual tumor

RAC

Ras-related c3 botulinum toxin substrate

RAF

rapidly accelerated fibrosarcoma

RANKL

receptor activator of nuclear factor kappa B ligand

RAS

GTPase protein family that includes KRAS, HRAS, and NRAS

RB1

retinoblastoma 1

RCC

renal cell carcinoma

RCVP

rituximab + cyclophosphamide + vincristine + prednisone

RECIST

Response Evaluation Criteria in Solid Tumors

RECIST v1.1

Response Evaluation Criteria in Solid Tumors version 1.1

RET

rearranged during transfection

RFS

recurrence-free survival

RFS2

time from randomization to recurrence on next therapy

RFS24

proportion of recurrence-free survival at 24 months

RFS36

proportion of recurrence-free survival at 36 months

RNA

ribonucleic acid

ROS1

ROS proto-oncogene 1

RP3D

recommended phase 3 dose

rPFS

radiographic progression-free survival

RT

radiotherapy

RTK

receptor tyrosine kinase

rwPFS

real-world progression-free survival

S phase

DNA replication phase

S6K

S6 kinase

SAE

serious adverse event

SBRT

stereotactic body radiation therapy

SCC

squamous cell carcinoma

scFv

single-chain variable fragment

SCLC

small cell lung cancer

SCRT

short course radiation therapy

sCRT

sequential chemoradiation therapy

SD

stable disease

SDMA

symmetric dimethylation of arginine

SERD

selective estrogen receptor degrader

SERM

selective estrogen receptor modulator

SLE

systemic lupus erythematosus

SLL

small lymphocytic lymphoma

SoC

standard of care

SOS

son of sevenless

ssDNA

single-stranded DNA

SSE-FS

symptomatic skeletal event-free survival

STAR-T

synthetic T cell receptor (TCR) and antigen receptor T-cells

STEAP2

six transmembrane epithelial antigen of prostate-2

STK11

serine/threonine kinase 11

STRIDE

Single Tremelimumab Regular Interval Durvalumab

SYK

spleen tyrosine kinase

T

tremelimumab

T-DM1

ado-trastuzumab emtansine

T-DXd

fam-trastuzumab deruxtecan-nxki in US only; trastuzumab deruxtecan in other regions of world

TACE

transarterial chemoembolization

TB

tuberculosis

tBRCAm

tumor BRCA mutated

TC

tumor cell

TCC

transitional cell carcinoma

TCE

T-cell engager

TCR

T-cell receptor

TDT

time to discontinuation or death

TEAE

treatment emergent adverse event

Teff

effector T cells

TFST

time to first subsequent therapy

TGFβ

transforming growth factor beta

TGFβRII

transforming growth factor, beta receptor II

TGFβRIIDN

dominant negative transforming growth factor, beta receptor II

TIGIT

T-cell immunoreceptor with immunoglobulin and ITIM domains

TILs

tumor-infiltrating lymphocytes

TKI

tyrosine kinase inhibitor

TMB

tumor mutation burden

TN

treatment-naïve

TNBC

triple-negative breast cancer

TNM

tumor node metastasis staging

TNM8

Tumor Node Metastasis 8th edition

TOP1i

topoisomerase 1 inhibitor

TP53

tumor suppressor protein 53

TPS

tumor proportion score

Treg

regulatory T cell

Trop-2

trophoblast cell-surface antigen 2

tSCLC

transformed small cell lung cancer

TSST

time to start of second subsequent therapy

TTC

time to chemotherapy

TTCR

time to the first castration-resistant event

TTD

time to treatment discontinuation

TTD

time to deterioration

TTDF

time to deterioration in fatigue

TTDM

time to death or distant metastases

TTDPF

time to deterioration in physical function

TTDUS

time to deterioration in urinary symptoms

TTNT

time to next treatment

TTP

time to progression

TTPP

time to pain progression

TTR

time to recurrence

TURBT

transurethral resection of bladder tumor

UC

urothelial cancer

UFT

tegafur-uracil

uHCC

unresectable hepatocellular carcinoma

ULN

upper limit of normal

uMRD

undetectable minimal residual disease

V

venetoclax

vc-MMAE

valine-citrulline monomethyl auristatin E

VHH

variable domain of the heavy-chain

VO

venetoclax plus obinutuzumab

Vp1

segmental portal vein

Vp3

first-order branch of the portal vein

Vp4

main trunk of the portal vein or contralateral first-order branch

VPI

visceral pleural invasion

WHO

World Health Organization

WHO PS

World Health Organization performance status

WT

wild type

XELOX

capecitabine, oxaliplatin

XRCC1

X-ray repair cross-complementing protein 1

ZAP70

zeta-chain-associated protein kinase 70